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Background. A measles outbreak occurred in Maroua, Cameroon, from January 2008 to April 2009. In
accordance with recent World Health Organization guidelines, an outbreak-response immunization (ORI) was
conducted in January 2009. The aim of this study was to investigate the causes of the epidemic in order to guide
vaccination strategies.
Methods. We performed a stratiﬁed household-based survey using cluster sampling to determine measles
vaccination coverage in children aged 9 months to 15 years. We deﬁned 3 strata based on measles incidence. Next,
we performed a case–control study to measure vaccine effectiveness (VE). Cases were obtained from health center
registries. Controls were selected among respondents to the coverage survey.
Results. The vaccination-coverage survey included 2963 children in total. The overall routine vaccination
coverage was 74.1% (95% conﬁdence interval [CI]: 70.0%–78.3%). Measles incidence was inversely proportional to
routine vaccination coverage, with high incidence associated with coverage of 71% and low incidence associated
with coverage of 84%. The overall VE was 94% (95% CI, 86.7%–97.4%). After the ORI in January 2009, the coverage
was .90% in all strata and measles incidence declined rapidly.
Discussion. Our results conﬁrm that insufﬁcient vaccination coverage was the main reason for this epidemic.
The ORI conducted in January 2009 contributed both to control the epidemic and to increase the vaccination
coverage to desirable levels.
Implementation of the comprehensive measles mortality–
reduction strategy by high-burden countries supported
by the Measles Initiative, a partnership supporting
measles mortality reduction in Africa, has resulted in
a .90% decline in measles-related mortality in the last
decade [1–3]. The 4-pronged strategy focuses on im-
proved routine immunization, providing all children
with a second opportunity for measles immunization
through either periodic supplemental immunization ac-
tivities (SIAs) or routine second doses of measles vaccine,
improved measles case management, and careful measles
surveillance[4].
In the last 10 years, Cameroon has seen great progress
in measles control. First-dose coverage has increased
from 47% in 2001 to 80% in 2008. Countrywide SIAs
were conducted in 2002 and 2006, with .90% admin-
istrative coverage in targeted populations (aged 9 mo–
14 y in 2002; aged 9 mo–59 mo in 2006) [1, 5]. Measles
surveillance and case management has also been re-
inforced. These interventions have contributed to a
reduction in the annual incidence from 41 cases per
100,000 children in 2001–2004 to 2 cases per 100,000
children in 2005–2008 [1].
Despite this progress, an outbreak was declared in the
Extreme-Nord region at the beginning of 2008. Most
cases were reported in the city of Maroua, with a total
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 of 875cases and 8 deathsreported between 1 January 2008 and 6
April 2009 (Figure 1a). The most affected area was the center
of the city, with an attack rate over 700 cases per 100,000 chil-
dren (Figure 1b). In response to the epidemic, several inter-
ventions were conducted: 1) Routine vaccination activities
were reinforced during 2008, 2) a vaccination intervention was
performed in certain affected health districts of Maroua in
October 2008, and because of the continued reporting of cases,
3) a mass vaccination campaign was implemented in late
January 2009 targeting all children aged 9 months to 15 years,
irrespective of their vaccination status.
TheWorldHealthOrganization(WHO) hasrecentlyupdated
guidelines for response to measles outbreaks in mortality-
reduction settings including outbreak-response immunization
(ORI) [6]. Few evaluations of the impact of reactive vaccination
in epidemics have been conducted [7–9]. To investigate the
causes of this epidemic, we performed a vaccination-coverage
survey and a case-control study to determine vaccine effective-
ness. The rationale for this investigation was to document the
reactive vaccination activities and provide additional
information for the control of measles in northern Cameroon.
METHODS
Vaccine-Coverage Survey
Design Overview Allchildrenli vinginthecityofMarouaatthe
timeofthestudyagedbetween9monthsand15yearswereeligible
for the survey. The sample was obtained using stratiﬁed cluster
sampling. We divided Maroua into 3 strata: [1] High-incidence
areas (17&); [2] intermediate-incidence areas (3&–6.9&); and
[3] low-incidence areas (0&–2.9&). We based the division of
strata on attack rates in each health district computed using the
number of cases reported to the Ministry of Health of Cameroon
and on populations from the most recent census (Figure 1b). In
each of these strata, we obtained a representative sample of the
population via spatial random sampling. To calculate sample size,
we assumed an alpha-error of .05, desired precision of 6 7%,
design effect of 3, and expected vaccination coverage of 65%,
75%, and 85% in the high-, intermediate-, and low-incidence
strata, respectively. Considering these assumptions, the mini-
mum sample size was estimated to be 535, 441, and 300 in these 3
strata, respectively, corresponding to 24, 20, and 14 clusters of 22
children each [10]. We evaluated children aged 9 months to 15
years from at least 18 households in each cluster.
Survey Teams Survey teams were recruited locally and
underwent a 2-day training prior to the initiation of ﬁeldwork.
Training consisted of survey methodology, interview method-
ology, and a pilot implementation of the questionnaire. Survey
teams comprised at least 1 male and 1 female. Survey-team
members spoke both French and Fulfulde, the language in
which most interviews were conducted. Each team surveyed 5
clusters of 18 households per day.
Cluster Allocation and Household Selection We allocated
clusters within the 3 incidence strata proportionally to the
population of each health district. Population data used to al-
locate clusters was provided by the regional Expanded Program
on Immunization (EPI) ofﬁce. To select households within
clusters, we used spatial-based sampling [11] employing a sat-
ellite photo from Google Earth. After demarcating each health
district, we randomly selected the desired number of starting
points for each one from a uniform distribution (Figure 2).
When a point was closer than 20 meters to a structure in the
satellite image, the point was selected. If not, the point was
discarded and another point was drawn at random. This process
ensured the same probability of selection for each structure. We
deﬁned households as individuals living and eating together
under the same roof. We selected households subsequent to the
ﬁrst by proximity. If a household was absent, we asked survey
teams to return to the household later in the day. If a household
was absent after 2 return attempts, the household was skipped
and replaced with another household.
Data Collection All information was elicited by interviews.
Interviews were conducted preferentially with the mother or
female caregiver. A standardized questionnaire was used to
collect demographicdata,vaccinationstatus, vaccination history
(place, date of vaccination, and injection site on the body),
reasons for nonvaccination, previous measles episodes, and
stays outside Cameroon in the preceding 6 months for each
child included in the survey. We veriﬁed vaccination status
retrospectively by vaccination cards provided either in the
routine vaccination or in the mass vaccination interventions.
When card veriﬁcation was not possible, history was relied on.
We also asked respondents their degree of literacy, place of
usual residence, and the number of children residing in the
household.
Deﬁnitions We employed the following deﬁnitions for the
vaccine-coverage survey.
n Vaccinated: an individual who had received R1 dose of
measles-containing vaccine. Vaccination was veriﬁed by
vaccination card or history.
n Unvaccinated: an individual who had no vaccination card
and whose parent or guardian conﬁrmed on interview that
she or he has received no measles vaccination.
n Routine vaccination: an individual who had received a dose
of measles-containing vaccine on the routine schedule. Routine
vaccination was veriﬁed either by its registration on a routine
vaccination card or by report during interview that the child
had received the ‘‘9-months vaccine.’’
n October 2008 intervention: excluding persons vaccinated
through the routine system, an individual with measles
vaccination registered on a vaccination card with date during
the intervention or for whom vaccination in October 2008
was conﬁrmed by report during interview.
S244 d JID 2011:204 (Suppl 1) d Luquero et al
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 Figure 1. (a) Weekly number of measles cases in Maroua (Cameroon) during weeks 1–52 of 2008 and 1–14 of 2009. (b) Measles attack rates by
sanitary area in Maroua at the end of the epidemic, April 2009.
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 n January 2009 mass vaccination campaign: excluding persons
vaccinated through the routine system, an individual with
vaccination registered on a vaccination card or for whom the
interviewedpersonreportedthatthechildhadreceivedadoseof
measles vaccine between 29 January 2009 and 5 February 2009.
Data Entry and Analysis Our main outcomes were meas-
ures of measles vaccine coverage in each incidence stratum and
an overall estimate of vaccination coverage for Maroua. Our
secondary outcomes included vaccine coverage by age group
and reasons for nonvaccination. We obtained crude vaccina-
tion-coverage estimates, considering the survey design. We
calculated the design effect to estimate the loss of precision
due to the cluster-based sampling strategy [12]. We obtained
adjusted vaccination-coverage estimates using generalized linear
and latent mixed models to account for household, cluster, and
area-level correlation [13]. We calculated sampling weights at
each level to account for the different cluster size. We used
EpiData 3.1 software for data entry and Stata 10.0 software for
data analysis.
Vaccine Effectiveness Assessment: Case-Control Study
Deﬁnition and Selection of Case and Control
Participants A case was deﬁned as any patient between age
9 months and 15 years who sought care at a governmental or
private health facility and who was registered in the surveillance
logbook as meeting the WHO measles case deﬁnition: fever,
maculopapular (ie, nonvesicular) rash, and cough, coryza (ie,
runny nose), or conjunctivitis (ie, red eyes). Case participants
also needed to be residents of Maroua with known vaccination
status.
Children included in the vaccination-coverage survey were
included in the case-control study as controls. Eligibility as
a control required: oral informed consent; residency in Maroua;
age between 9 months and 15 years; known vaccination status
and no previous measles episode.
For each case, we enrolled 4 controls that were individually
matched to the case date of birth (6 3 mo) and health district
of residence. To control for potential differences in vaccine ef-
fectiveness throughout the period of investigation, we selected
3 different dates of analysis (1 January–30 September 2008, 15
November 2008–28 January 2009, and 19 February–17 April
2009); we deﬁned cases and controls for each period to calculate
vaccine effectiveness (Table 1).
Ascertainment of Vaccination Status and Potential
Confounding Variables We followed the same procedure
described for controls and we used the surveillance-system
register for cases. We cross-checked the information in the
surveillance database with the registers of the health centers
when possible. The variables considered as possible confounders
were age, place of residency (matching variables), and sex.
Statistical Analysis We assessed associations between
vaccination status in the 3 different periods (Table 1) and
case–control status through conditional logistic regression, with
case–control status as the dependent variable and the exposure
variable of interest as the independent variable. The exponential
ofthe coefﬁcientforthevaccinationvariableinthesemodelswas
computed to estimate the adjusted odds ratio, and the standard
error of the coefﬁcient was used to estimate the P value and
95% conﬁdence interval (CI). To estimate the adjusted level of
Figure 2. Distribution of the randomly selected starting points (black
dots) in the different sanitary areas.
Table 1. Definition of Cases and Controls, Vaccine Effectiveness Study, Maroua, Cameroon, April 2009
Measurement: Vaccine Effectiveness Cases
a Controls
a Exposure
Routine immunization
until October 2008
Registered cases from 1 January
to 30 September 2008
4 controls that were
individually matched to
each case by date of
birth (63 mo) and sanitary
area of residence
Vaccination through the
routine activities
Routine immunization 1 October
2008 intervention
Registered cases from 15
November 2008 to 28 January 2009
Vaccination through the
routine activities or the
October 2008 intervention
Routine immunization 1 October
2008 intervention 1 January
2009 campaign
Registered cases from19 February
to 17 April 2009
Vaccination through the
routine activities, the
October intervention, or the
January 2009 campaign
NOTE.
a The inclusion and exclusion criteria were applied in each substudy: age between 9 mo and 15 y, resident of Maroua, known vaccination status.
S246 d JID 2011:204 (Suppl 1) d Luquero et al
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 vaccine protection, we computed the following value for the
vaccination variable: (1 – adjusted odds ratio) 3 100.
We interpreted all P values and 95% CIs in a 2-tailed fashion.
We deﬁned statistical signiﬁcance as a P value , .05.
Ethical Considerations
This study adhered to the principles that govern biomedical
research involving human participants. We followed the
Declaration of Helsinki, aiming to provide assurance that the
rights, integrity, and conﬁdentiality of participants were pro-
tected [14]. We obtained oral consent from participants or
their parents or guardians. We ensured privacy and conﬁden-
tiality in the data collected from the participants both during
and after the conduct of the study. We entered and analyzed
all information anonymously. To verify vaccination status re-
ported through the surveillance data (health center registers),
the names of all the children were recorded in one separate sheet
of paper. After the dedicated survey teams inspected the medical
records to verify information, this sheet of paper was destroyed
by the supervision team. This was the only point during the
survey that we recorded information on individual children.
We implemented the study in collaboration with the Ministry
of Health after obtaining authorization to perform the survey
from the Division of Operational Research of the Ministry of
Health of Cameroon.
RESULTS
Description of the Children Included in the Survey
The survey was conducted between 13 and 17 April 2009. The
vaccine-coverage survey included 2963 children. The mean age
of these children was 6.9 years (standard deviation [SD], 4.02 y),
and there were slightly fewer boys (49.9%) than girls. Most of
the children did not report traveling outside Cameroon in the
preceding 6 months (98.6%).
There werenostatisticaldifferencesintheage orthesex ofthe
children by strata. We observed a higher percentage of illiterate
caregivers in the high–measles-incidence strata, but without
statistical differences (Table 2).
Description of Vaccination Status
Regarding routine immunization, 74.1% of the children (95%
CI, 70.0%–78.3%) were vaccinated through routine service
delivery. It was reported that 28.1% of the children (95% CI,
22.3%–33.9%) had been vaccinated through the targeted vac-
cination intervention in October 2008. A high percentage of
children were vaccinated in the January 2009 mass campaign:
79.7% (95% CI, 76.4%–82.9%).
We computed the immunization coverage of children who
had received R1 dose of measles vaccine following routine
vaccination, after the targeted vaccination in October 2008, and
after the January 2009 campaign (Table 3). We found a statistical
difference (P , .001) in the routine coverage among strata. Only
after the January 2009 campaign was the coverage .90% in all
3 measles-incidence strata. The stratiﬁed analysis by age showed
lower routine coverage inthe youngest children, as lowas 66% in
children aged 9–24 months. The coverage was lower in those
children with an illiterate caregiver (coverage ratio,1.26; 95% CI,
1.17–1.33) (Table 3).
Written records of vaccination were available to ascertain
vaccination status for only 20% of the children vaccinated
through the routine immunization and ,2% of those vacci-
nated during the mass campaigns. Nonetheless, .95% of re-
spondents reported the geographical location where the vaccine
was administered for the 3 vaccination activities, and most
identiﬁed the shoulder as the site of injection (routine, 86.0%;
October 2008 5 95.7%; January 2009 5 94.6%). The exact date
ofthe routinevaccinationwas unknown for mostofthe children
who reported oral vaccination (98%).
Nonvaccinated Children and Reasons for Nonvaccination
Of the 662 children not vaccinated through the routine system,
most were vaccinated during the January–February 2009
campaign (52.0%; 95% CI, 41.9%–62.0%); 159 remained un-
vaccinated at the date of the survey (6.1%; 95% CI, 4.1%–8.2%).
The main reason for non vaccination of children in the routine
activitieswasrefusal(25.1%;95%CI,15.3%–34.9%).Thesecond
most frequent was ‘‘lack of information’’ (22.8%; 95% CI,
15.1%–30.5%). For those children not vaccinated during
the October intervention or the January campaign, the main
reason was ‘‘lack of information’’ (36.2%; 95% CI,
29.4%–43.0%). Some mothers reported not being allowed to
Table 2. Description of the Children Included in the Coverage
Survey by Incidence Strata, Maroua, Cameroon, 2009
High
Incidence
Middle
Incidence
Low
Incidence
Variable % (95% CI) % (95% CI) % (95% CI)
Age
%5 y 43.5 (40.2–46.8) 42.4 (39.7–45.1) 41.4 (36.5–46.3)
. 5 y 56.5 (53.2–59.8) 57.6 (54.9–60.3) 58.6 (53.7–63.5)
Gender
Male 52.3 (49.3–55.4) 48.3 (44.4–52.2) 48.6 (44.4–52.8)
Female 47.7 (44.6–50.7) 51.7 (47.8–55.6) 51.4 (47.2–55.6)
Main
caregiver
Mother 87.8 (83.1–92.6) 83.2 (78.2–88.2) 79.7 (73.0–86.5)
Father 4.0 (1.1–6.9) 8.6 (4.2–13.0) 6.6 (2.5–10.7)
Other 8.2 (4.7–11.6) 8.2 (5.7–10.7) 13.7 (8.7–18.6)
Literacy
a
No 77.8 (70.4–85.2) 72.3 (63.4–81.1) 65.7 (52.0–79.4)
Yes 22.2 (14.8–29.6) 27.7 (18.9–36.6) 34.3 (20.6–48.0)
NOTE. CI, conﬁdence interval. 95% conﬁdence intervals calculated
considering the design effect.
a Literacy of the caregiver deﬁned as the ability to read and write.
Measles Outbreak in Maroua, Cameroon d JID 2011:204 (Suppl 1) d S247
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 Table 3. Vaccine Coverage Through the Routine Activities and After Each Intervention, Maroua, Cameroon, April 2009
Categories Vaccine coverage 95% CI Deff CR 95% CI ACR 95% CI
Routine immunization
Strata
High incidence 70.6 (64.4–78.6) 5.9 Ref Ref
Intermediate incidence 74.1 (66.4–81.8) 7.5 1.05 (.91–1.21) 1.05 (.95–1.16)
Low incidence 84.4 (80.1–88.7) 1.6 1.20 (1.10–1.30) 1.16 (1.09–1.24)
Age
9–23 mo 66.1 (59.2–73.1) 1.3 Ref
24–59 mo 74.4 (70.2–78.7) 1.8 1.12 (.01–1.25) 1.14 (1.02–1.26)
5–9 y 74.8 (70.1–79.5) 2.8 1.13 (1.02–1.25) 1.14 (1.03–1.25)
10–15 y 75.7 (70.2–81.2) 2.9 1.14 (1.05–1.25) 1.15 (1.05–1.26)
Sex
Male 73.7 (69.0–78.4) 3.9 Ref
Female 74.4 (70.1–78.7) 3.3 1.01 (.95–1.07)
Caregiver
Mother 73.8 (69.8–77.8) 4.8 Ref
Father 81.2 (68.8–93.7) 4.3 1.10 (.97–1.24)
Other 72.3 (53.6–91.0) 7.7 .98 (.79–1.22)
Literacy of the caregiver
Illiterate 69.7 (65.3–74.2) 4.7 Ref Ref
Literate 87.8 (84.0–91.5) 2.3 1.26 (1.17–1.35) 1.25 (1.17–1.33)
Number of children
1–2 children 73.8 (70.01–77.5) 3.3 Ref
3–5 children 75.2 (69.4–80.8) 3.5 1.02 (.98–1.07)
. 5 children 71.6 (53.2–90.0) 2.5 .98 (.80–1.20)
After October 2008 intervention
Strata
High incidence 75.4 (68.7–82.1) 7.7 Ref Ref
Intermediate incidence 84.8 (77.0–92.1) 11.5 1.13 (.97–1.30) 1.13 (1.02–1.25)
Low incidence 88.8 (84.7–93.0) 1.9 1.18 (1.06–1.31) 1.16 (1.05–1.27)
Age
9–23 mo 71.3 (63.6–78.9) 1.7 Ref Ref
24–59 mo 81.6 (77.2–86.0) 2.4 1.14 (1.03–1.27) 1.15 (1.04–1.27)
5–9 y 81.7 (77.1–86.0) 3.5 1.14 (1.03–1.26) 1.15 (1.04–1.26)
10–15 y 82.6 (77.0–88.2) 3.9 1.16 (1.04–1.29) 1.16 (1.04–1.28)
Sex
Male 80.7 (75.8–85.5) 5.2 Ref
Female 81.2 (76.8–85.5) 4.1 1.01 (.96–1.06)
Caregiver
Mother 80.6 (76.3–84.8) 6.7 Ref
Father 90.4 (80.3–100.5) 5.0 1.12 (.99–1.26)
Other 78.1 (60.9–95.4) 8.1 .97 (.83–1.14)
Literacy of the caregiver
Illiterate 77.3 (72.7–82.0) 6.0 Ref Ref
Literate 92.4 (89.6–95.2) 2.0 1.19 (1.10–1.30) 1.18 (1.10–1.27)
Number of children
1–2 children 80.4 (76.5–84.4) 4.6 Ref
3–5 children 82.7 (77.0–88.5) 4.7 .93 (.98–1.09)
. 5 children 74.7 (55.5–94.0) 3.0 .93 (.77–1.13)
After January–February 2008 intervention
Strata
High incidence 92.3 (88.4–96.2) 7.3 Ref
Intermediate incidence 95.0 (92.8–97.1) 2.5 1.03 (.98–1.08) 1.03 (.98–1.07)
Low incidence 95.8 (94.1–97.6) .9 1.04 (.99–1.08) 1.03 .99–1.07
S248 d JID 2011:204 (Suppl 1) d Luquero et al
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 make a decision regarding vaccination in both routine and
campaigns (6.7%).
Vaccine Effectiveness Study
The vaccine effectiveness was close to 95% in the 3 periods
(prior to the October 2008 intervention, October 2008–January
2009 intervention, and post-January 2009 intervention), with-
out statistical differences between them (Table 4). The per-
centage of controls vaccinated progressively increased over
the 3 periods in line with the increase in citywide coverage.
Cases exhibited a similar trend with the percent vaccinated
higher at the end of the study period.
DISCUSSION
The results of this investigation suggest that the measles epi-
demic observed from October 2008 to April 2009 in Maroua
was due to insufﬁcient vaccination coverage. The most plausible
explanation for the epidemic is that routine coverage was
not extensive enough to contain the epidemic. In addition, the
study demonstrates high vaccine effectiveness, in keeping with
low routine coverage as the main causative factor. The routine
coverage differed among the geographical strata examined in
the study and was inversely correlated with the measles in-
cidence in each area. This reinforces the hypothesis that low
routine vaccine coverage was the main reason for the epidemic.
Vaccine coverage was .90% only after the mass vaccination
campaign of January–February 2009, with a subsequent de-
crease in the number of reported measles cases. The coverage of
the target population with R1 dose of measles vaccine reached
after the mass campaign conducted by the Ministry of Health
was .90% even though the ORI covered %80% of the targeted
children. This experience demonstrates that such campaigns
Table 3. (Continued)
Categories Vaccine coverage 95% CI Deff CR 95% CI ACR 95% CI
Age
9–23 mo 84.5 (79.4–89.5) 1.2 Ref Ref
24–59 mo 93.9 (91.0–96.8) 2.9 1.12 (1.05–1.19) 1.11 (1.05–1.17)
5–9 y 95.3 (93.3–97.4) 2.5 1.14 (1.08–1.20) 1.11 (1.06–1.77)
10–15 y 94.7 92.5–96.9 1.8 1.13 (1.06–1.20) 1.09 (1.03–1.16)
Sex
Male 93.7 (90.7–96.7) 5.4 Ref
Female 94.0 (92.3–95.6) 1.8 1.00 (.97–1.03)
Caregiver
Mother 93.3 (90.9–95.7) 5.6 Ref Ref
Father 96.5 (92.7–100.2) 1.9 1.04 (.99–1.09) 1.01 (.97–1.06)
Other 97.6 (95.5–99.8) 1.2 1.05 (1.01–1.08) 1.05 (1.01–1.08)
Literacy of the caregiver
Illiterate 92.7 (90.0–95.4) 5.6 Ref Ref
Literate 92.7 (95.4–99.0) 2.2 1.05 (1.02–1.08) 1.05 (1.02–1.08)
Number of children
1–2 children 92.8 (90.7–94.9) 3.2 Ref Ref
3–5 children 95.9 (93.6–98.2) 3.0 1.03 (1.02–1.05) 1.03 (1.01–1.05)
. 5 children 99.2 (97.5–100.8) .5 1.07 (1.04–1.10) 1.07 (1.04–1.10)
NOTE. 95% CI, 95% conﬁdence interval; Deff, design effect; CR, coverage ratio; ACR, adjusted coverage ratio; Ref, reference value.
Table 4. Total Numbers of Cases and Controls, Percentage of Children Vaccinated, and Vaccine Effectiveness for Each Vaccination
Period
Cases Controls
Intervention n % vaccinated n % vaccinated VE
a 95% CI
Routine 54 13.0 170 73.5 96.4 (88.0–98.9)
Routine 1 October 2008 361 8.6 870 80.7 97.7 (95.9–98.7)
Routine 1 October 2008 1 January 2009 72 44.4 240 94.2 94.2 (86.7–97.4)
NOTE. VE, vaccine effectiveness; 95% CI, 95% conﬁdence interval.
a Vaccine effectiveness: adjustment was performed using a conditional logistic regression matched by age and residency place and adjusted by sex.
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 can help to control outbreaks and to increase the vaccine
coverage to desirable levels.
The recently revised WHO guidelines for response to measles
outbreaks in mortality-reduction settings advise the use of
measles vaccine as a control measure [6]. This recommendation
was revised based on evidence suggesting that there is enough
time to perform vaccination campaigns before the natural end
of the outbreak, thereby reducing cases and subsequent deaths
[15–17]. Our work documents one of the ﬁrst interventions
performed following the new WHO recommendation. Time is
important when conducting ORIs, and it was a limitation of the
mass campaign implemented in Maroua. The campaign was
performed late in the epidemic, and its potential impact would
have been higher with earlier implementation. This highlights
the importance of supporting governments to revise existing
measles control and elimination plans to include ORI as a key
strategy to reduce measles related mortality. The WHO, the
United Nations Children’s Fund (UNICEF), Me ´decins Sans
Frontie `res, and other health actors should continue to advocate
for the use of measles vaccine as soon as possible in outbreak
situations.
Even with the presence of routine immunization and the 2
supplemental vaccination interventions in Maroua, 6% of
all children never received measles-containing vaccine. This
emphasizes the need for strategies speciﬁcally addressing those
children who have little or no contact with health structures and
are missed in mass campaigns. Although the reported reasons for
nonvaccination are subject to recall bias and interviewer bias, and
should be taken only as a rough indication, the principal reason
cited was lack of information. The second reported cause for
nonvaccination was refusal to accept vaccination. Many hypoth-
eses consider why caregivers may refuse vaccination—restrictions
on female heads of households accompanying their children
without the male heads of households; fear of side effects; lack
of understanding of the potential gravity of nonvaccination;
mistrust of the health system; and lack of means if they are re-
quired to pay for services. However, these hypotheses remain
untested and require a speciﬁcally designed study to investigate
the different reasons for vaccine refusal in Maroua.
It is similarly important to note the limitations of this in-
vestigation. First, because caregivers may not accurately recall
history, children without vaccination cards reporting non-
vaccination may have indeed been vaccinated. To minimize
misclassiﬁcation, we asked parents to describe in which clinic
their child received the vaccine and by way of what part of
the body the vaccine was delivered (eg, shoulder, elbow, mouth)
to check whether the parent correctly remembered a vaccine
consistent with measles-vaccine delivery. The possibility of
response bias is always present; however, previous studies in
areas of high measles incidence have shown parental recall to be
highlyreliable[18]. Toincrease the sensitivityand speciﬁcity, we
also used the local term for measles during the interviews [19].
In addition, some vaccinations received through countrywide
SIAs (2002 and 2006) could have been classiﬁed as routine
vaccinations, which could explain the higher routine coverage in
older children.
Second, our study design relied on available population data
for each of the administrative areas. Because a cluster random-
ized design, our allocation of clusters was based on population
size. If there were large differences between actual and estimated
population, this may have led to a less-than-optimal sample
selection. However, becasuse we included a large population size
and covered the entire urban area, estimates of vaccine coverage
should be robust to differences in the true population sizes.
Further, we used the best available maps of the administrative
areas to design our survey. However, these maps may mis-
represent the true boundaries of the areas. Thus, we may have
erroneously included individuals in one cluster when they
should have been allocated to another.
Because there is limited serological conﬁrmation of the cases
in this outbreak, we relied on respondent-reported history of
previous measles episodes and health-center registries. Using
a case deﬁnition of clinically conﬁrmed cases, rather than
laboratory-conﬁrmed cases, introduces the possibility of in-
advertently including cases of rubella and other exanthemas
[20]. This is a difﬁcult limitation to overcome without per-
forming concurrent serological testing. If misclassiﬁcation is
present, it could lead to an increase in the number of vaccinated
children among reported cases, thereby decreasing the effec-
tiveness estimate [21]. A similar bias, in the same direction, may
result from health care–seeking behavior, if vaccinees sought
care more frequently than nonvaccinees. Alternatively, an
overestimation of the vaccine effectiveness would be observed
if mild, vaccinated cases did not attend the clinics, resulting
in a higher estimate of the proportion of unvaccinated in-
dividuals among reported cases; in this event, the effectiveness
estimate would reﬂect the vaccine’s ability to prevent severe
cases. Moreover, it is also likely that unvaccinated children
may have had greater exposure to the measles virus, as vaccine
coverage was inversely related to incidence strata. We have tried
to reduce this bias by adjusting the analysis for place of resi-
dence. Because ascertainment was obtained mostly through
oral reporting, misclassiﬁcation of vaccination status may have
occurred, but it is unlikely that this bias would affect cases more
than controls [21].
In light of the results of this investigation and considering the
afore-mentioned key limitations, we can still conclude that the
measles outbreak in Maroua was principally due to insufﬁcient
routine coverage, especially in the youngest children of some
areas of the city. We found vaccination coverage differed within
geographic strata, which warrants an additional analysis of the
catchment populationand theirexperienceswiththe health-care
system. Data concerning differences in access to care and health-
center operations (eg, opening hours, vaccine availability,
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 stafﬁng) may reveal how to better serve this population.
Although the January 2009 campaign was successful, strategies
to ensure that absent residents participate in future campaigns
could be considered. Measles control in Maroua is largely
a success story; nonetheless, this outbreak shows the importance
of keeping high routine vaccine coverage and maintaining
effective supplemental activities.
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